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Abstract
Reprogramming of energy metabolism is pivotal to cancer, so mitochondria are potential targets for anticancer therapy. A
prior study has demonstrated the anti-proliferative activity of a new class of mitochondria-targeting rosamines. This present
study describes in vitro cytotoxicity of second-generation rosamine analogs, their mode of action, and their in vivo efficacies
in a tumor allografted mouse model. Here, we showed that these compounds exhibited potent cytotoxicity (average
IC50,0.5 mM), inhibited Complex II and ATP synthase activities of the mitochondrial oxidative phosphorylation pathway and
induced loss of mitochondrial transmembrane potential. A NCI-60 cell lines screen further indicated that rosamine analogs 4
and 5 exhibited potent antiproliferative effects with Log10GI50 =27 (GI50 = 0.1 mM) and were more effective against a
colorectal cancer sub-panel than other cell lines. Preliminary in vivo studies on 4T1 murine breast cancer-bearing female
BALB/c mice indicated that treatment with analog 5 in a single dosing of 5 mg/kg or a schedule dosing of 3 mg/kg once
every 2 days for 6 times (q2d66) exhibited only minimal induction of tumor growth delay. Our results suggest that rosamine
analogs may be further developed as mitochondrial targeting agents. Without a doubt proper strategies need to be devised
to enhance tumor uptake of rosamines, i.e. by integration to carrier molecules for better therapeutic outcome.
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Introduction
Conventional cancer chemotherapy depends on drugs that act
by interrupting DNA replication, i.e. by inhibiting the synthesis or
function of new nucleic materials, or by causing irreparable
damage to vital nucleic acids through intercalation, alkylation or
enzymatic inhibition. Lack of selectivity for neoplastic cells
exhibited by these drugs typically limits their success as treatment
agents. Contemporary chemotherapeutic strategies that target
signaling pathways or particular gene products tend to be limited
to cancers driven by a dominant oncogene and are often
vulnerable to resistance via the multiplicity of tumorigenesis
signaling pathways [1]. For example, most of the HER-2 positive
metastatic breast cancer patients who initially responded to
treatment with trastuzumab develop secondary trastuzumab
resistance within a year after the treatment began [2]. Similar
observations have been made for BRAF-targeted vemurafenib for
melanoma therapy [3] and EGFR-targeted gefitinib or erlotinib
for the treatment of non-small cell lung cancer [4].
A relatively new alternative to targeting DNA and enzymes in
rapidly proliferating cells, or specific signaling pathways is to focus
on organelles like the mitochondria. Mitochondria are the energy
generators that maintain cell life and essential cell functions,
including multiple signaling cascades that regulate cells, for
instance, metabolism, cell cycle control, development, and cell
death [5]. In cancer chemotherapy, mitochondria-targeting drugs
interfere with cancer cell metabolisms by pertubing the mito-
chondrial transmembrane potential, inhibiting the electron redox
chain complexes, interfering the mitochondria transmembrane
permeability, and targeting mitochondrial-DNA [6,7]. The most
common types of mitochondria-targeting drugs are lipophilic,
cationic drugs; these are selective for cancer cells because they tend
to have higher mitochondrial membrane potentials than normal
epithelial cells [8,9].
We have previously reported structure-activity relationships
(SARs) for the anticancer properties of a series of rosamines
(Fig. 1A) [10,11]. These compounds are delocalized lipophilic
cations (DLC) with peripheral cyclic amines and various groups at
the meso position; the majority of these cations are substantially
more potent than rhodamine-123 which is a well-studied
delocalized lipophilic cation. Consistence with this, SAR data for
the rosamines suggested good potencies correlated with hydro-
phobic cyclic amines and meso-aryl substituents. Thiofuryl and 4-
iodophenyl meso substitution corresponded to approximately 5-fold
improvement in potency compared to phenyl substitution.
Additionally, the data indicated that significantly lower IC50
values were obtained for unsymmetrical compounds (X1 not same
as X2), but the combination of unsymmetrical amine substituents
with thiofuryl and 4-iodophenyl meso substitution was not explored.
Intracellular imaging on representative examples indicated these
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compounds accumulate in the mitochondria. These compounds
(i.e rosamine 2 and 5) are also found to be more cytotoxic against
cancer cells compared with immortalized normal epithelial cells of
the same organ type [10].
The research reported here was undertaken to probe how two
molecular modifications affect cytotoxicities in this series: (i)
replacement of para-iodo or thiofuran groups with other para-
halide or furan groups; and, (ii) combination of thiofuryl and 4-
iodophenyl meso substitution with piperidine/morpholine combi-
nations. Thus we report syntheses of second generation rosamines
(Fig. 1B) and their cytotoxicities relative to a panel of solid tumor
cell lines. Compounds with promising activity were further
evaluated in the NCI-60 human tumor cell lines screen. Selected
rosamines were also examined for their effect on cellular redox
systems and for effects in an in vivo tumor model.
Materials and Methods
Ethics Statement
All animal experiments were conducted in accordance with
protocols reviewed and approved by Dr. Haji Azizuddin Bin Haji
Kamaruddin, Laboratory Animal Centre (LAC) Animal Care and
Use Committee of Faculty of Medicine, University of Malaya
(reference number FAR/14/07/2010/LSH). Female BALB/c
mice aged between 6–8 weeks with a minimum weight of 17 g
were maintained in a controlled environment of 12 h light-dark
cycles with free access to food (standard pellet diet purchased from
Figure 1. Structural variations of rosamine. (A) of the rosamine dyes variously functionalized at the meso position as previously reported by Lim
et al. (Anticancer Drugs 2009, 20: 461–468), the ones shown here with meso- thiofuran or 4-iodophenyl had superior anticancer activities in cellular
assays. (B) Second-generation targets featured in this work.
doi:10.1371/journal.pone.0082934.g001
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Altromin International, Lage, Germany) and purified water.
Female mice were used because the hormonal environment
essential for development of implanted 4TI mouse mammary
carcinoma would be present.
Materials
Minimum essential medium with Earl’s salt and L-glutamine,
RPMI 1640 medium with L-glutamine, fetal bovine serum, Pen-
Strep (10 000 U/ml penicillin, 10 mg/ml streptomycin), trypsin
106 were supplied by GIBCO, Invitrogen (Auckland, New
Zealand). JC-1 was purchased from Molecular Probes, Invitrogen
(Oregon, USA). Dimethyl sulfoxide (DMSO), hydrochloric acid
37%, polyethylene glycol 400 (PEG 400) and 2-propanol were
purchased from Merck (Hohenbrunn, Germany). Ethylene glycol-
bis(aminoethylether)-tetra-acetic acid (EGTA), ethylenediaminetet-
raacetic acid (EDTA), 3-(N-morpholino)propanesulfonic acid
(MOPS), potassium chloride, potassium dihydrogen orthophos-
phate, sodium chloride, sodium hydrogen carbonate, disodium
hydrogen orthophosphate anhydrous, sucrose and Tris were
purchased Fisher Scientific (Leicestershire, UK). Thiazoyl blue
tetrazolium bromide (MTT) was purchased from Amresco (Ohio,
USA). Saline (0.9% sodium chloride) was obtained from Duo-
pharma Sdn. Bhd. (Selangor, Malaysia). Carbonyl cyanide 3-
chlorophenylhydrazone (CCCP) was purchased from Sigma
(Steinheim, Germany). Protein assay dye reagent concentrate was
obtained from Bio-Rad Laboratories (California, USA). Complex I,
Complex II, Complex IV and ATP synthase enzyme activity
microplate assay kit were purchased from MitoSciences (Oregon,
USA).
Syntheses of Rosamine Analogs
Rosamines were synthesized and purified as described previ-
ously [11]. The starting material of xanthone ditriflate was
prepared in solution by triflation of the phenols, followed by
animation of the triflate with piperidine to give symmetrical cyclic
amines substitution (Fig. 2A) or by stepwise addition of piperidine
and morpholine to give unsymmetrical cyclic amines substitution
(Fig. 2B) [11]. The resulted 3,6-diamino-xanthen-9-one was
reacted with organolithium or Grignard reagents to yield the
desired rosamine structures.
In general, a Grignard reagent or lithium reagent (1.0 mmol)
was added dropwise over 1 min to the solution of 0.2 mmol 3,6-
diamino-xanthen-9-one in 5 ml of THF at 0uC. The reaction
mixture was stirred for 12 h at room temperature. After
completion of reaction, 2 ml of 2 M aqueous HCl was added,
stirred for 10 min to quench the reaction and diluted with 20 ml of
CH2Cl2. The organic layer was washed with water and brine,
dried over anhydrous Na2SO4, and concentrated under reduced
pressure. The residue was purified by flash chromatography (5%
to 10% MeOH/CH2Cl2) to give the pure product.
Spectral data for the synthesized compounds are listed here
except the synthesis and spectral data for rosamines 1, 2 and 5
were as previously reported [11]. They are named below in a way
that describes the meso-substituents and assumes the compound is
symmetrical unless otherwise indicated.
4-Bromobenzene Rosamine 3. 1H NMR (300 MHz,
CDCl3) d 7.72 (d, 2H, J=8.4 Hz), 7.27–7.21 (m, 4H), 7.09 (dd,
2H, J=9.6, 2.6 Hz), 6.94 (d, 2H, J=2.6 Hz), 3.74–3.70 (m, 8H),
1.74 (br, 12H); 13C NMR (75 MHz, CDCl3) d 158.1, 156.3, 155.0,
132.2, 131.6, 130.9, 130.5, 124.9, 115.0, 113.3, 97.4, 49.1, 25.9,
24.0; lmax abs 570 nm, lmax emiss 590 nm, e 110800 M
21 cm21,
fwhm 38 nm, W 0.7860.02 in CH2Cl2; HRMS (ESI) m/z calcd
for (M-Cl)+ C29H30BrN2O 501.1542; found 501.1539.
4-Chlorobenzene Rosamine 4. 1H NMR (300 MHz,
CDCl3) d 7.56 (d, 2H, J=8.4 Hz), 7.30 (d, 2H, J=8.4 Hz),
7.26 (d, 2H, J=9.6 Hz), 7.09 (dd, 2H, J=9.6, 2.4 Hz), 6.95 (d,
2H, J=2.4 Hz), 3.74–3.70 (m, 8H), 1.74 (br, 12H); 13C NMR
(125 MHz, CDCl3) d 158.1, 156.3, 155.1, 136.7, 131.6, 130.8,
130.1, 129.3, 115.0, 113.4, 97.5, 49.2, 25.9, 24.1; lmax abs 570 nm,
lmax emiss 590 nm, e 119100 M
21 cm21, fwhm 38 nm, W
0.8060.02 in CH2Cl2; HRMS (ESI) m/z calcd for (M-Cl)
+
C29H30ClN2O 457.2047; found 457.2052.
Furan Rosamine 6. 1H NMR (500 MHz, CDCl3) d 7.97 (d,
2H, J=9.7 Hz), 7.92–7.91 (m, 1H), 7.18 (dd, 2H, J=9.7, 2.6 Hz),
7.15–7.14 (m, 1H), 6.90 (d, 2H, J=2.6 Hz), 6.82–6.81 (m, 1H),
3.74–3.72 (m, 8H), 1.76 (br, 12H); 13C NMR (125 MHz, CDCl3)
d 158.2, 156.0, 147.3, 145.7, 142.2, 132.0, 120.5, 115.0, 113.3,
111.8, 97.5, 49.0, 25.9, 24.1; lmax abs 592 nm, lmax emiss 627 nm,
e 86900 M21 cm21, fwhm 105 nm, W 0.3860.01 in CH2Cl2;
HRMS (ESI) m/z calcd for (M-Cl)+ C27H29N2O2 413.2229; found
413.2232.
Unsymmetrical 4-Iodophenyl Rosamine 7. 1H NMR
(300 MHz, CDCl3) d 7.96 (d, 2H, J=8.3 Hz), 7.35–7.29 (m,
2H), 7.17–7.09 (m, 6H), 3.88 (t, 4H, J=4.7 Hz), 3.78–3.71 (m,
8H), 1.77 (br, 6H); 13C NMR (75 MHz, CDCl3) d 158.6, 157.9,
156.9, 156.7, 155.9, 138.2, 131.9, 131.5, 131.1, 131.0, 115.5,
114.6, 114.0, 113.7, 98.6, 97.9, 97.1, 66.4, 49.5, 47.4, 26.1, 24.0;
lmax abs 565 nm, lmax emiss 586 nm, e 80900 M
21 cm21, fwhm
39 nm, W 0.5260.02 in CH2Cl2; HRMS (ESI) m/z calcd for (M-
Cl)+ C28H28IN2O2 551.1195; found 551.1192.
Unsymmetrical Thiofuryl Rosamine 8. 1H NMR
(500 MHz, CDCl3) d 7.69 (dd, 1H, J=4.8, 1.4 Hz), 7.62 (d,
1H, J=9.7 Hz), 7.59 (d, 1H, J=9.7 Hz), 7.26–7.22 (m, 2H), 7.19
(dd, 1H, J=9.7, 2.5 Hz), 7.09 (dd, 1H, J=9.7, 2.5 Hz), 7.00 (d,
1H, J=2.5 Hz), 6.90 (d, 1H, J=2.5 Hz), 3.78 (t, 4H, J=4.9 Hz),
3.68–3.65 (m, 8H), 1.67 (br, 6H); 13C NMR (75 MHz, CDCl3) d
158.1, 157.5, 156.6, 156.3, 149.8, 132.2, 132.0, 131.7, 130.6,
130.6 (two peaks: 130.62, 130.56), 128.2, 115.2, 114.6, 114.3,
114.0, 97.8, 97.2, 66.2, 49.1, 47.2, 25.9, 23.9; lmax abs 576 nm,
lmax emiss 599 nm, e 87600 M
21 cm21, fwhm 42 nm, W
0.3060.01 in CH2Cl2; HRMS (ESI) m/z calcd for (M-Cl)
+
C26H27N2O2S 431.1793; found 431.1795.
Cell Culture and In Vitro Cell Viability Assay
MCF-7 breast carcinoma and HCT-116 colon carcinoma cell
lines were obtained from American Tissue Culture Collection
(Virginia, USA) and maintained in RPMI 1640 medium supple-
mented with 10% FBS. HSC-2 oral cavity human squamous
carcinoma cells were obtained from Health Science Research
Resources Bank (Japan). HK-1, a previously characterized naso-
pharyngeal squamous carcinoma cells [12] is a gift by Prof. Wong
Y.C. from the University of Hong Kong. Both cell lines were grown
in MEM medium supplemented with 10% FBS. For cell viability
assay, cells at 4000 cells/well in 80 ml of medium were inoculated in
96-well plates and were allowed to adhere overnight. Cells were
then treated with each compound at concentrations ranging from
0.001–10 mM giving the final volume of 100 ml in each well. At the
end of incubation period, 15 ml of 5.0 mg/ml MTT in phosphate
buffered saline (PBS) was added and incubated for 4 h. Medium
and excessive MTT were aspirated and the resulting formazan was
solubilized with 100 ml of dimethyl sulfoxide. Absorbance was read
at 570 nm with SpectraMax M4 microplate spectrophotometer
(Molecular Devices, CA).
NCI-60 Human Tumor Cell Line Screen
NCI-60 cell panel screening was performed by the NCI/
National Institutes of Health developmental therapeutics program
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(Bethesda, US). This platform allows the determination of growth
inhibitory profiles of test compounds on 60 different human cancer
cell lines, representing leukemia, melanoma and cancers of the
lung, colon, central nervous system, ovary, breast, prostate, and
renal subpanel. Sulforhodamine B assay was used to assess the
cytotoxicity of test agents in a panel of 60 cell lines [13]. Briefly,
the human tumor cell lines of the cancer screening panel were
grown in RPMI 1640 medium containing 5% FBS and 2 mM L-
glutamine. For a typical screening experiment, cells were
inoculated into 96 well microtiter plates in 100 ml at plating
densities depending on the doubling time of individual cell lines.
After cell inoculation, the microtiter plates are incubated at 37uC,
5% CO2 and 100% relative humidity for 24 h. Following
incubation, aliquots of 100 ml of compound at different dilutions
were added to the appropriate microtiter wells and were further
incubated for 48 h. At the assay end-point, cells were fixed with
trichloroacetic acid followed by Sulforhodamine B staining for
cellular protein content. Sulforhodamine B absorbance was read at
a wavelength of 515 nm as a measurement of cell density.
Mitochondria Isolation and Detergent Solubilization
Functional mitochondria were isolated from mouse liver by
differential centrifugation method [14]. Briefly, a mouse (,30 g) was
starved overnight before sacrificed by cervical dislocation. The liver
was harvested promptly and rinsed with ice-cold mitochondria
isolation buffer (10 mM Tris-MOPS, 1 mM EGTA/Tris, 0.2 M
sucrose, pH 7.4) until blood-free. The liver was then cut into small
pieces in a beaker using scissors while keeping in an ice-bath. The
buffer was replaced with 5 ml of fresh isolation buffer and the liver
was homogenized with a Polytron probe (Ultra-Turrax T8, Ika-
Werke, Germany) until smooth. The homogenate was centrifuged at
1000 g for 15 min at 4uC. The pellet was discarded and the
supernatant was centrifuged at 12000 g for 15 min at 4uC to pellet
the mitochondria. The mitochondria were washed twice by
resuspending in 4 volumes of isolation buffer containing 16protease
cocktail inhibitor. The concentration of the mitochondrial protein
was determined using the Bradford (Biorad protein assay) method.
The mitochondria were frozen in 10 mg/ml aliquot at 280uC.
Detergent solubilization of the mitochondria proteins was done
prior to measurement of the oxidative phosphorylation complexes
activity. Mitochondria were diluted to 5.5 mg/ml with PBS and
solubilized by addition of a 1/10th volume of detergent provided
to give the final protein concentration of 5 mg/ml. The mixture
was incubated on ice for 30 min and centrifuged at 17 000 g at
4uC for 20 min. The supernatant was collected and diluted to
appropriate concentration for each oxidative phosphorylation
complexes activity.
Figure 2. Schematic illustration of the synthesis of rosamines. (A) The starting material of xanthone ditriflate was prepared in solution by
triflation of the phenols, followed by animation of the triflate with piperidine to give symmetrical cyclic amines substitution or; (B) by stepwise
addition of piperidine and morpholine to give unsymmetrical cyclic amines substitution.
doi:10.1371/journal.pone.0082934.g002
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Measurement of Oxidative Phosphorylation Complexes
Activity
Measurements of mitochondria oxidative phosphorylation
activities for Complex I, II, IV and ATP-synthase were carried
out using the microplate immunocapture ELISA assay kit
according to their respective manufacturer’s protocols [15]. In
general, plate pre-coated with appropriate immunocapture anti-
body was incubated with mitochondria extract at recommended
concentration to allow immobilization of their respective com-
plexes. Complexes activity was measured by addition of substrates
solution mix provided by the kit and compound was added at
concentration ranging from 0.01–10 mM in triplicate. Control
wells treated with only 0.1% DMSO (v/v) and wells without
mitochondria extract incubation were included as background
reference. The kinetic of the complexes activity was recorded with
SpectraMax M4 microplate spectrophotometer reader using the
suggested measurement parameters.
JC-1 Analysis of Mitochondrial Membrane Potential
The mitochondrial membrane potential was measured based on
the potential–dependent accumulation of the cationic JC-1 dye
which results in a shift of fluorescence emission from green
(,525 nm) to red (,590 nm) due to the formation of J-aggregates
[16]. Therefore, mitochondrial depolarization is indicated by a
decrease in the red/green fluorescence intensity ratio. Briefly, cells
were collected and suspended in 1 ml warm media at approx-
imately 16106 cell/ml. In a control tube, 1 ml of 50 mM CCCP
was added and incubated at 37uC for 5 min. Then, 10 ml of
200 mM JC-1 was added into the cells and incubated at 37uC for
30 min. Cells were washed twice with warm PBS, resuspended in
500 ml of PBS and analyzed on a FACSCalibur flow cytometer
using 488 nm excitation with 530/30 nm and 585/42 nm
bandpass emission filters.
In Vivo Antitumor Efficacy
Tumor allografts were initiated by subcutaneous injection of
56105 4T1 mouse mammary carcinoma in 0.1 ml RPMI 1640
media into the inguinal mammary fat-pads of mice [17]. Tumor
growth was monitored and treatments were initiated when tumors
reached volume of approximately 200 mm3. To assess the tumor
growth inhibition, 4T1 tumor bearing mice were randomized into
groups with at least eight animals per group. Compound 5 was
prepared at 0.3 mg/ml in normal saline and treatment was
administered intravenously at 5 mg/kg on staging day or 3 mg/
kg every other day for six treatments (q2dx6). For control group,
normal saline was given. The animal weights and tumor volume
were measured three times weekly for 14 d. The tumor volume was
calculated using the equation: (length6width2)/2 and relative tumor
volume (RTV) was calculated for every tumor volume at any given
time (VT) against the tumor volume at staging day (V0) using the
equation: VT/V0. The RTV – time profile for each group was
plotted and tumor growth delay in attaining a specified number of
doublings compared to control was determined [18,19]. Results
were expressed as median 695% confidence interval (n= 8).
Statistical Analysis
Statistical significance were performed using one-way ANOVA
post hoc with Bonferroni test (SPSS 16.0, IBM Corporation,
Armonk, NY) and difference were considered significant when
P,0.05.
Results and Discussion
Rosamine Analogs
Our previous study indicated structures meso-substituted with 4-
iodobenzene 2 and thiofuran 5 were 5-fold more active than the
phenyl substituted compound 1. Compounds 3, 4 and 6 were
synthesized to test if meso-replacement with 4-bromobenzene 3, 4-
chlorobenzene 4 or 2-furyl 6 groups would affect the anticancer
activity. In addition, the 4-iodobenzene 7 or 2-thiofuran meso
substituents 8 and unsymmetrical piperidine/morphine amine
substituents were synthesized and investigated. Rosamines 1–4
and 7 were not appreciably water-soluble so they were reconsti-
tuted in DMSO at 10 mM as treatment stock. Rosamines 5, 6 and
8 were readily solubilized in aqueous media at similar concentra-
tions, so were used without DMSO.
In Vitro Antitumor Efficacy of Rosamine and NCI-60
Screen
The in vitro antitumor activity of rosamines was assessed using a
48 h endpoint cell viability methylthiazolyldiphenyl-tetrazolium
bromide (MTT) assay against a panel of solid human tumor cell
lines including breast carcinoma (MCF-7), colon carcinoma
(HCT-116), oral squamous cell carcinoma (HSC-2) and nasopha-
ryngeal carcinoma (HK-1). The IC50 values for these rosamines
across the panel of cancer cell lines tested ranged from 0.07–
1.2 mM as summarized in Table 1. From this study, rosamines
bearing phenyl halide or heterocyclic moieties were significantly
(P,0.05) more potent than phenyl substituted rosamine 1. Halide
substitution resulted in improvement of cytotoxicity; this was
expected because substitution of H by halide is commonly used to
increase compound lipophilicity that improves lipid-bilayer
membrane permeability [20]. Within the halide series, cytotoxic-
ities increase in the following order 4.3.2 (Cl.Br.I), although
not statistically significant (P.0.05). The compounds with meso-
heterocyclic substituents 5 and 6 were more potent than the
aromatic halides 2–4. Of the two compounds with meso-
heterocycles the thiofuran-substituted 5 was slightly more active
than 6, the furan-substituted one.
Compounds 7 and 8 have a more polar combination of amine
substituents than the symmetrical bispiperidine 2, and they proved
to be more cytotoxic (Table 1). This is consistent with our previous
data for 2-methylbenzenes unsymmetrically substituted with
Table 1. Antiproliferative activities of rosamine analogs
against a panel of cancer cell lines.
Rosamine Activity IC50 (mM)
a
MCF-7 HCT-116 HSC-2 HK-1 Meanb
1 1.260.7 0.6060.41 0.0960.00 0.6160.07 0.63 {
2 0.5960.12 0.3960.07 0.3560.05 0.2960.03 0.41 `
3 0.2960.04 0.3060.08 0.1960.11 0.3460.00 0.28 `,1
4 0.1560.04 0.2260.14 0.0960.01 0.2560.01 0.18 `,1
5 0.1860.02 0.0760.02 0.0960.01 0.1060.00 0.11 1
6 0.3160.14 0.1060.03 0.0960.00 0.3160.08 0.20 `,1
7 0.2660.07 0.2460.07 0.2260.10 0.4460.01 0.29 `,1
8 0.1760.10 0.0760.02 0.2260.11 0.5360.00 0.25 `,1
aIC50, the concentration of compound, which inhibits the viability by 50% as
compared with control untreated cells. Values represent the mean 6 SD of at
least three determination assessed 48 h post-treatment using
methylthiazolyldiphenyl-tetrazolium bromide assay.
bDifferent symbols ({, `, and 1) indicate statistically significant differences
(P,0.05) among the mean values.
doi:10.1371/journal.pone.0082934.t001
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piperidine and morpholine which showed nearly 2-fold lower IC50
values compared with the symmetrical hydrophobic structure
containing only piperidine [10]. Meanwhile for the meso-thiofuran
5, substitution of one of the piperidine groups with morpholine
gives 8, which has a slightly decreased activity, contrary to our
expectations.
Figure 3. NCI-60 cell lines screen. GI50 (50% growth inhibition) mean graphs showing the activity patterns of 4, 5 and methyl violet (NSC271967)
in the NCI-60 cell line screens. Both the rosamines exhibited potent antiproliferative effects with Log10GI50 =27 (GI50 = 0.1 mM) and were particularly
more effective against colorectal cancer panel. COMPARE analyses indicated 4 and 5 have similar pattern of activity as methyl violet with Pearson
correlation coefficient values of 0.767 and 0.72, respectively.
doi:10.1371/journal.pone.0082934.g003
Oxidative Phosphorylation Targeting Rosamines
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Rosamines can exhibit phototoxicity due to generation of
reactive oxygen species in the presence of light. To test for this, a
duplicate plate was irradiated with 5.3 J/cm2 of broad spectrum
light for 2 h after compound treatment in parallel with a plate
maintained in the dark. There were no significant differences in
IC50 values obtained between both irradiated and non-irradiated
experiments (data not shown) indicating phototoxicity was not an
issue.
On the basis of the findings above, rosamines 4 (NSC751819)
and 5 (NSC751817) were submitted for NCI-60 human tumor cell
lines screen to provide more information on the growth inhibitory
profiles against 60 different human cancer cell lines, representing
leukemia, melanoma and cancers of the lung, colon, central
nervous system, ovary, breast, prostate, and renal subpanel. This
platform allows the mode of action to be inferred by comparing
with the drug-activity patterns of standard agents with known
targeting characteristics using COMPARE (computerized pattern-
recognition algorithm) analyses [21]. The GI50 values generated
from the NCI-60 cell lines screen indicated that both rosamine 4
and 5 exhibited potent antiproliferative effects with
Log10GI50 =27 (GI50 = 0.1 mM) and were particularly more
effective against a sub-panel of colorectal cancer cell lines (Fig. 3).
COMPARE analyses indicated that both these rosamines had
similar patterns of activity with methyl violet (NSC271967), a
cationic triarylmethane dye which has been formerly used in
Figure 4. Loss of mitochondrial transmembrane potential.
Representative event of mitochondrial transmembrane potential loss in
HSC-2 cells treated with 2 and 5 at 0.1 mM. Following 8 h of treatment
with 2 and 5, the percentage of cell population with mitochondrial
transmembrane potential loss increased to 19% and 34%, respectively.
The percentage depolarized cell of untreated control at 8 h remains at
8%, while for positive control, cells treated with 5 mM of carbonyl
cyanide 3-chlorophenylhydrazone (CCCP) for 5 min results in 70%
depolarized cell population. *Difference with P-value,0.05 compared
to control at 0 h.
doi:10.1371/journal.pone.0082934.g004
Figure 5. Inhibition of mitochondrial oxidative phosphorylation complexes. The dose-response inhibition of mitochondrial oxidative
phosphorylation Complex 1 (A), Complex II (B), Complex IV (C) and ATP synthase (D) activities by rosamine 2 (solid line) and 5 (dotted line). The
activity of Complex II was partially inhibited by 5 with IC50 value of 9.660.1 mM whereas for 2, inhibition was observed but with undetermined IC50
value. Both 2 and 5 also inhibited the ATP synthase activities with IC50 values of 3.960.3 and 3.060.8 mM respectively. The activity of Complex I and
Complex IV were not affected by the rosamines at the treated concentrations (highest at 10 mM). IC50 values depict concentration that inhibits the
complexes activity by 50%. ND - indicate non-determined IC50 values based on the concentration used.
doi:10.1371/journal.pone.0082934.g005
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medicine for its antimicrobial, antifungal and antihelmintic
properties. This class of dyes had been shown to promote
mitochondrial respiratory inhibition by inhibiting ATP synthesis,
dissipating mitochondrial membrane potential and inducing
mitochondrial permeability transition [22,23]. Thus the NCI-60
cell lines screen indicated the compounds tested had a signature
unique to energy metabolism-targeting anticancer agents.
Rosamines Interfered the Energy Redox
We have previously demonstrated that rosamines primarily
localize in the mitochondria [10] and that accumulation of
cytotoxic DLC is known to alter mitochondrial transmembrane
potentials [24,25]. Thus, alterations of mitochondrial membrane
potential caused by rosamines 2 and 5 were monitored based on
the accumulation of potential-dependent JC-1 dye which resulted
in a shift of fluorescence emission from green (,525 nm) to red
(,590 nm) due to the formation of J-aggregates. From the study,
HSC-2 cells treated with 2 at 0.1 mM, 9% of the cell population
exhibited the onset of mitochondrial transmembrane potential loss
within 1 h after treatment and gradually increased to 19%
(P,0.05) in 8 h (Fig. 4). Meanwhile, the mitochondrial trans-
membrane potential loss was more prominent in HSC-2 cells
treated with 5 at 0.1 mM. Approximately 21% (P,0.05) of the cell
population was affected in the first hour and the percentage
increased drastically to 34% in 8 h. For the untreated control cells,
the population of depolarized cells at 8 h remained at approxi-
mately 8%. Meanwhile, cells treated with 5 mM of CCCP for
5 min resulted in loss of membrane potential in 70% (P,0.05) of
cell population. CCCP is an oxidative phosphorylation decoupling
agent which acts as a positive control for the experiment.
To further understand the mitochondria inhibition featured by
the rosamines, their effect on the oxidative phosphorylation
pathway was investigated. Using immunocapture ELISA micro-
plate assay, the enzyme kinetics of mitochondrial redox carriers
Complex I, Complex II, Complex IV and ATP-synthase were
monitored upon treatment with 2 or 5. The activity of Complex II
(Fig. 5B) was partially inhibited by 5 with IC50 value of
9.660.1 mM whereas for 2, inhibition was observed but did not
reach 50% up to maximum concentrations studied. Meanwhile,
both 2 and 5 displayed inhibition of ATP synthase activities
(Fig. 5D) with IC50 values of 3.960.3 mM and 3.060.8 mM
respectively. The activity of Complex I and Complex IV (Fig. 5A
and 5C) were not affected by the rosamines at concentrations up to
the maximum used, 10 mM. These data suggest that rosamines 2
or 5 compromise mitochondrial bioenergetics primarily by
inhibiting ATP synthase, a proton-driven enzyme that produces
ATP from ADP and inorganic phosphate. Similar biochemical
interaction was observed in rhodamine-123 and this effect is
expected as the compound has close structural similarity with the
rosamines [26].
In Vivo Antitumor Effect of Rosamines
Rosamine 5 was selected for further evaluation in in vivo tumor
model given its in vitro potency and ability to achieve aqueous
solubility large enough for preparing an intravenous injection
without the need of formulation. As illustrated in Fig. 6A, tumor
growth attenuation was observed at experimental end-point (day
14) when mice received single bolus of 5 mg/kg of 5 i.v. compared
control group (P=0.08). The tumor growth attenuation effect is
further enhanced (P=0.029) when mice received rosamine
treatment regimen at 3 mg/kg, once every 2 day, for 6 times
(q2d66). The median day for 4T1 tumor in attaining two-
doubling growth (RTV=4) were approximately 9, 11 and 13 days
in control mice, mice receiving 5 mg/kg and 3 mg/kg (q2d66)
respectively. The determined percentage of two-doubling tumor
growth delay (T-C)/C in mice treated with 5 mg/kg and 3 mg/kg
(q2d66) of 5 were 22% and 38%, respectively.
Meanwhile, the terminal percent test/control (% T/C) values
calculated at the end of experiment were 72% and 66% in mice
receiving 5 mg/kg and 3 mg/kg (q2d66) respectively. The
antitumor efficacy of 5 is minimal as the % T/C attained after
treatment had ended is not #40% activity, the minimal rating for
a compound to be considered active [18]. Loss of body weight
(Fig. 6B) was observed in mice treated with 5 throughout the
experimental period, however the reduction at any time were not
statistically significant compared to the untreated mice. None of
the mice suffer weight loss more that 15%, the cut-off limit set in
the experiment [27].
Figure 6. In vivo antitumor effects of rosamine. (A) The relative
tumor volume (RTV) – time profile of 4T1 murine breast carcinoma in
Balb/C mice following intravenous dosing of rosamine 5 or saline as
vehicle control. Each point represents median 695% confidence
interval of RTV to staging day (n = 8). The terminal % T/C value for
mice receiving 5 mg/kg and 3 mg/kg (q2d66) of 5 were 72% and 66%
respectively. The two doubling tumor growth delay (T-C)/C (dotted line,
RTV = 4) for mice receiving a single bolus of 5 mg/kg and multiple doses
of 3 mg/kg (q2d66) of 5 were 22% and 38%, respectively. T and C refer
to RTV for treatment and control groups, respectively. *Difference with
P-value,0.05 compared to control animal. (B) Percentage of mean body
weight of mice received 5 mg/kg or 3 mg/kg (q2d66) of 5 compared to
untreated mice. Body weight loss was observed in treatment groups
but none of these mice experienced weight loss of more than 15%.
doi:10.1371/journal.pone.0082934.g006
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From this study, the in vivo anticancer effect shown by 5 is
minimal, probably because 4T1 was an aggressive tumor cell line
and the dose of compound 5 used was modest. However, use of a
higher concentration was not possible because unacceptable
adverse effects such as weight loss, diarrhea and sudden death
were observed at 10 mg/kg dose.
Even though these rosamines (i.e 2 and 5) are more cytotoxic
against cancer cells compared with normal epithelial cells
(previously published data [10]), their effects on normal cells
could still lead to undesirable side effects as a result of increase
lactic acid accumulation in cells following decreased ATP synthase
activity and a shift in metabolic pathways from aerobic to
anaerobic metabolism. Accumulation of lactic acid has been
shown to cause depressive cardiovascular function, cardiac
arrhythmias and multiple organ failure. Therefore, risk minimi-
zation measures to deal with lactic acidosis such as those employed
in the management of patients prescribed with metformin, a
commonly used antidiabetic drug with similar toxic side effects,
need to be outlined to prevent this serious complication [28,29].
Another documented side effect commonly associated with
DLC such as rosamines is selective accumulation of these
compounds in cardiac muscle cells that can lead to fatal
deterioration in the function of the heart muscle [30]. Studies
have shown that cardiac muscle cells are similar to cancer cells in
that both also exhibit high negative plasma membrane potentials
which encourage increased uptake of DLC. In connection to this,
doxorubicin which is a positively charged antracycline antitumor
agent, was also shown to target the cardiac muscle cells and caused
serious and occasionally fatal cardiotoxicity in a significant
number of treated cancer patient [31]. However, following
liposomal encapsulation of doxorubicin, cardiotoxicity was dimin-
ished in cancer patients receiving the formulation with no loss of
efficacy [32]. It therefore remains to be investigated whether a
similar encapsulation approach with the rosamines could also
decrease their toxicity while maintaining the efficacy.
Conclusions
The in vitro results demonstrated that the rosamines investigated
here inhibit the proliferation of cancer cell-lines with IC50 value at
nanomolar concentrations, with rosamine 5 being the most active.
NCI-60 cell lines screen showed that these compounds are
particularly effective against the colorectal cancer panel of cells
and COMPARE analysis revealed a strong correlation in growth
inhibitory pattern exhibited by mitochondrial respiratory inhibitor
i.e. crystal violet. The anticancer effects of these compounds may
have been due to their ability to compromise mitochondrial
membrane potential and to inhibit the oxidative phosphorylation
complexes primarily the ATP synthase which were both exper-
imentally observed in this study. Although the preliminary in vivo
antitumor activity of 5 is moderate against 4T1 murine mammary
tumor, it may be worthwhile to test the compound in colon cancer
xenograft models, for example, models based on HCT-116 and
HT-29 cell lines which are both more sensitive to 5 on NCI-60 cell
line screen. However further study is needed to diminish the toxic
effects observed for this compound.
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